Novo Nordisk weight-loss pill drives first-quarter profit beat
Reuters reports the oral Wegovy launch is central to Novo's effort to close the gap with Eli Lilly in obesity.
The wire
- 01Novo Nordisk reported first-quarter results that beat profit expectations, with the oral weight-loss pill cited as a key contributor.
- 02Oral semaglutide uptake matters for pharmacies and telehealth operators planning inventory and patient switching from injectables.
- 03Detailed pill-by-pill sales splits and durability of the launch trajectory remain to be seen in coming quarters.
From the source
Read at reuters.comNovo Nordisk weight-loss pill powers profit beat in race to catch Eli Lilly